Epithelial ovarian cancer (EOC) is the most fatal gynecologic malignancy due to its late diagnosis and lack of curative therapy. The antimalaria compound artemisinin and its derivatives, such as artesunate (ART) and dihydroartemisinin (DHA), have proven to be potent anticancer drugs and act through various anticancer mechanisms. To identify novel targets of artemisinin derivatives in EOC cells, we investigated the effects of ART and DHA on SKOV3 and primary EOC cell growth via CCK-8 assay. Both ART and DHA inhibited EOC cell growth. A cell cycle distribution analysis showed that ART and DHA caused G2/M cell cycle arrest. Moreover, ART and DHA induced autophagy in EOC cells, whereas autophagy inhibitors reversed the cell growth inhibition and cell cycle arrest induced by ART and DHA. Western blot analysis showed that ART and DHA also suppressed the cell cycle-related NF-κB-signaling pathway in EOC cells. These data suggest that artemisinin derivatives induce autophagy, block the cell cycle, and inhibit cell growth in EOC cells. Our research provides new targets for artemisinin derivatives for EOC treatment.
Introduction
Epithelial ovarian cancer (EOC) is the fourth most common cause of cancer-related deaths in women and the most lethal gynecological cancer, with a poor prognosis and a 5-year survival rate of only 40% [1] . Surgery can reduce the tumor burden, provide a histopathological diagnosis, and establish the Federation of Gynecology and Obstetrics (FIGO) stage. Most patients with advanced disease initially benefit from platinum-based chemotherapy but relapse within 18 months [2, 3] . Efforts have been made to improve therapeutic efficacy. For example, vascular endothelial growth factor inhibitors, such as bevacizumab, are used for antiangiogenic therapy [4] . Nanomedicine has been applied to drug delivery for more efficient chemotherapy [5] . However, the survival rate of patients has changed little over the past few decades [6] . Therefore, it is important to explore alternative anticancer strategies.
Increasing evidence has highlighted the anticancer potential of artemisinin and its derivatives [7] . Artemisinin, which was discovered in the 1970s by Tu Youyou's group as an antimalarial drug, shows high efficacy and low toxicity [8] . Semisynthetic derivatives, including artemether, artesunate (ART) and dihydroartemisinin (DHA), are more soluble and stable. Furthermore, new derivatives have been synthesized, and their properties as anticancer agents have been demonstrated [9] . Several articles have reported the anticancer effects of artemisinin derivatives on ovarian cancer, and possible mechanisms have been elucidated. Wang et al. [10] reported that ART induced oxidative stress and double-strand DNA breaks, downregulated the homologous recombinational repair protein RAD51, and consequently sensitized ovarian cancer cells to cisplatin. DHA inhibited the adhesion, invasion, and migration of EOC cells in vitro, as well as their growth and metastasis in vivo [11] . In addition, the DNA damage and cell death effects induced by ART may be partly reactive oxygen species (ROS)-dependent in ovarian cancer [12] .
Autophagy is a self-digestion process in which cellular components are sequestered in double-membraned vesicles and then degraded in lysosomes [13] . Autophagy plays an important role in tumor cell metabolism because deprivation of oxygen and nutrients often occurs in cancer cells [14] . Controversy remains regarding the role of autophagy in cancer. Artemisinin and its derivatives seem to be autophagy inducers in cancer [15] . However, whether autophagy participates in the anti-EOC mechanism of artemisinin derivatives has not been reported.
In the current study, we evaluated the effects of the artemisinin derivatives ART and DHA on cell growth inhibition and cell cycle arrest in both SKOV3 cells and primary cultured EOC cells. We found that ART and DHA produced anticancer effects and induced autophagy in EOC cells, which might lead to cell cycle arrest. Furthermore, the cell cycle-related NF-κB-signaling pathway was inhibited in EOC cells by the artemisinin derivatives. These results suggest that artemisinin derivatives might be a new target for EOC treatment.
Materials and Methods

Cell culture and reagents
The ovarian cancer cell line SKOV3 was obtained from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The EOC primary cells were obtained from one patient sample, which was categorized as stage III, grade 2-3 serous adenocarcinoma according to the International FIGO classification. The present study was approved by the Institutional Review Board of Shanghai Jiao Tong University, and informed consent was obtained from the patient of International Peace Maternity and Child Health Hospital (Shanghai, China). The patient tissue sample was cut into pieces and incubated with 0.25% trypsin-EDTA (Biological Industries, Kibbutz Beit Haemek, Israel) at 37°C for digestion. Then, the suspension was filtered and centrifuged to collect the cells. The primary EOC cells used in the experiments had undergone fewer than 10 passages. The cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) (HyClone, Utah, USA) supplemented with 10% fetal bovine serum (Biological Industries) and 100 U/ml penicillinstreptomycin (Yeasen, Shanghai, China) in a humidified environment containing 5% CO 2 at 37°C. ART and DHA were purchased from Sigma-Aldrich (St Louis, USA). ART was dissolved in doubledistilled water. DHA was first dissolved in dimethyl sulfoxide (DMSO) and diluted to working concentrations with double-distilled water. The final concentration of DMSO in the medium was <0.1%. Chloroquine (CQ), bafilomycin A (BAF), and rapamycin were purchased from Sangon Biotech (Shanghai, China).
CCK-8 assay
Cell viability was assessed using Cell Counting Kit-8 (CCK-8) (Yeasen) according to the manufacturer's instructions. Cancer cells were harvested and seeded in 96-well plates at 5000 cells per well. The cells were cultured overnight, and the previous medium was discarded. ART and DHA solutions with or without autophagy inhibitors were added in gradients. After 24 h, cell viability was measured.
Cell cycle analysis
Cells were cultured with or without the artemisinin derivatives for 24 h, collected, washed with phosphate buffer saline (PBS), and fixed in 70% ethanol at −20°C overnight. Then, the cells were treated with 0.1 mg/ml RNase A (Yeasen) and stained with propidium iodide (PI) (KeyGEN, Nanjing, China) according to the manufacturer's protocols. The samples were analyzed in triplicate, and the cells were subject to cell cycle analysis with a flow cytometer (BD Accuri C6; BD Biosciences New Jersey, USA).
Apoptosis assay
An Annexin V-FITC/PI Apoptosis Detection Kit (40302ES20; Yeasen) was used to detect apoptosis. After receiving the designated treatments, cells were digested with trypsin (Lonza, Basel, Switzerland) and then centrifuged (4°C, 300 g, 5 min) for collection. Then, the cells were washed with ice-cold PBS twice, and 10 5 cells were suspended in 100 μl of 1× binding buffer and incubated with 5 μl of Annexin V-FITC and 10 μl of PI for 15 min in the dark at room temperature. Then, 400 μl of 1× binding buffer was added, and the cell apoptosis rate was measured with the flow cytometer.
Western blot analysis
Protein was extracted from cell lysates using radioimmunoprecipitation assay buffer (Beyotime, Shanghai, China), and the concentrations were quantified using a bicinchoninic acid assay kit (Boster, Wuhan, China). Western blots were obtained using standard protocols. Antibodies against LC3 (wl01506; Wanleibio, Shenyang, China), p65 (8242 T; CST), p-p65 (3033 T; CST), Beclin-1 (4122 S; CST), Atg5 (wl02411; Wanleibio), and β-tubulin (30303ES10; Yeasen) were used as primary antibodies. Enhanced chemiluminescence kit (New Cell & Molecular Biotech Co., Suzhou, China) was applied to visualize the blots. The results were quantified with ImageJ software (NIH, Maryland, USA).
GFP-LC3 plasmid transfection and autophagic flux assay
Cells were seeded on glass-bottomed dishes (In Vitro Scientific, Mountain View, USA). After overnight culture, they were transfected with a GFP-LC3 plasmid (gifted by Dr Junlin Guan at the University of Cincinnati) at 80% confluence using Lipofectamine 3000 reagent (Thermo Fisher Scientific Inc., Waltham, USA). Twenty-four hours later, the cells were treated with ART or DHA, and the rapamycin group was used as a positive control. After another 24 h, the number of cells with GFP-LC3 puncta in three random visual fields was determined for each group. Images were acquired with a Leica Application Suite X (LASX) confocal microscope (Leica TCS SP8, Wetzlar, Germany).
siRNA transfection
Cells were transfected with siRNA using Lipofectamine 3000 reagent according to the manufacturer's instructions. The sequence of negative control (NC) (sense: 5′-UUCUCCGAACGUGUCACGUTT-3′, anti-sense: 5′-ACGUGACACGUUCGGAGAATT-3′) and sequence of Atg5 siRNA (sense: 5′-GCAACUCUGGAUGGGAUUGUU-3′, anti-sense: 5′-CAAUCCCAUCCAGAGUUGCUU-3′) were described previously [16] . siRNA was synthesized by GenePharma Co.
(Shanghai, China). The cells were then incubated for 24 h and subject to western blot analysis or cell viability assay.
Statistical analysis
Student's t-test was used to analyze the data. The P-values were calculated using GraphPad Prism version 6 (GraphPad Software, La Jolla, USA). Differences were considered statistically significant when P < 0.05.
Results
Artemisinin derivatives inhibit the growth of EOC cells by inducing G2/M cell cycle arrest
To test the anticancer effects of artemisinin derivatives on EOC cells, we chose ART and DHA, which are commonly used in cancer research [17] . CCK-8 cell viability assay was used to investigate the growth inhibition activity of the two derivatives against the human ovarian cancer cell line SKOV3 and an EOC primary cell culture. The cancer cells were cultured in complete medium with different concentrations of ART or DHA (0, 2.5, 5, 10, 20, 40, 50, 60, and 100 μM). It was found that the cell viability was decreased in a dose-dependent manner in artemisinin derivative-treated ovarian cancer cells (Fig. 1A) .
To determine whether the cell growth inhibition of artemisinin derivatives is due to cell cycle arrest, 0, 30, or 50 μM ART or DHA was added to EOC cells, and the cell cycle distribution was analyzed by flow cytometry. As shown in Fig. 1B , compared with the control group, the proportion of cells in the G2/M phase was significantly increased after ART or DHA treatment in both SKOV3 cells and primary EOC cells. These effects were also dose-dependent, suggesting that artemisinin derivatives can induce cell cycle arrest.
Then, we tested whether apoptosis is involved in the deactivation of EOC cells. Annexin-V/PI staining assay showed that the percentages of apoptotic cells were similar in the artemisinin derivativetreated groups and the control group (Fig. 1C) . These results demonstrated that artemisinin derivatives arrested the cell cycle of EOC cells at the G2/M phase but did not induce obvious apoptosis, indicating that the cell growth inhibition might be due to cell cycle arrest ( Supplementary Fig. S1C ).
Artemisinin derivatives induce autophagy in EOC cells
Autophagy is a programmed process in which cellular proteins and organelles are degraded. It is a major cellular pathway that responds to environmental alterations [18] . Gong et al. [19] found that autophagy induction could arrest the G2/M transition via upregulation of p21, a cyclin-dependent kinase inhibitor, in pancreatic cancer cells, breast cancer cells, and lung cancer cells, suggesting that autophagy may play a role in cell cycle regulation. The conversion of LC3 from LC3-I to LC3-II is a reliable marker of autophagy [20] . We next examined whether autophagy in EOC cells can be induced by artemisinin derivatives. ART and DHA, at 0, 30, and 50 μM, were used to treat EOC cells for 24 h, and the autophagy level was analyzed by western blot analysis. EOC cells were treated with different concentrations of ART or DHA for 24 h. High LC3-II/LC3-I ratios were observed in both SKOV3 cells and primary EOC cells ( Fig. 2A,  B) . In addition, the induction of autophagy was dose-dependent. Another autophagy marker, Beclin-1, was also examined and found to be increased in ART/DHA-treated EOC cells, implying autophagy activation ( Fig. 2A,B) .
To further confirm autophagy stimulation, we transfected cells with GFP-LC3 expression plasmids. The autophagy activator rapamycin (0.5 μM) was used as a positive control. Under conditions of autophagy activation, punctate fluorescent structures formed, indicating autophagosome formation. After incubation with the artemisinin derivatives, both SKOV3 cells and primary EOC cells formed bright GFP-LC3 puncta, and a high percentage of puncta-positive cells were observed (Fig. 2C,D) . These results demonstrated that the artemisinin derivatives could induce autophagy in EOC cells at different concentrations.
The anti-EOC effects of artemisinin derivatives are reversed by an autophagy inhibitor
To confirm whether autophagy is the upstream mechanism of artemisinin derivative-induced G2/M arrest in EOC cells, we treated EOC cells with artemisinin derivatives (0, 30, and 50 μM) combined with CQ and BAF, two autophagy inhibitors. In vitro, 50 μM CQ or 50 nM BAF effectively inhibits autophagy in ovarian cancer cells ( Supplementary Fig. S1A ,B,D) [21] . As shown in Fig. 3A , artemisinin derivative treatment alone decreased cell viability; however, when the autophagy inhibitors were added, EOC cell viability was significantly increased. We also investigated whether blocking autophagy by knocking down Atg5, an essential autophagy gene, with siRNA could increase the survival percentage (Fig. 3A,b,d) . The knockdown efficacy was evaluated by western blot analysis (Fig. 3C) . The results demonstrated that the EOC cell growth inhibition induced by artemisinin derivatives was decreased when autophagy was interrupted.
Additionally, we tested whether inhibiting autophagy could interrupt the cell cycle arrest induced by artemisinin derivatives. As described above, 50 μM ART or DHA was sufficient to induce G2/M arrest in EOC cells; thus, 50 μM ART or DHA in combination with or without CQ was added to EOC cells. The results showed that ART and DHA induced G2/M phase arrest in SKOV3 and primary EOC cells, but when the artemisinin derivatives were used in combination with CQ, the proportion of EOC cells in the G2/M phase was significantly reduced (Fig. 3B and Supplementary Fig. S1C ). These results indicated that the cell cycle arrest induced by the artemisinin derivatives may depend in part on autophagy regulation in EOC cells.
Artemisinin derivatives regulate the NF-κB pathway via autophagy
We next measured whether the artemisinin derivatives could regulate the NF-κB-signaling pathway. It is generally accepted that when the NF-κB-signaling pathway is activated, p65 is phosphorylated to p-p65 and then translocates from the cytoplasm to the nucleus to activate target genes [22] . Therefore, reduction in p-p65 level is an indicator of NF-κB suppression. SKOV3 and primary EOC cells were treated with ART (0, 30 or 50 μM) or DHA (0, 30, and 50 μM) for 24 h, and then the p65 and p-p65 protein levels were analyzed by western blot analysis. As shown in Fig. 4A ,B, the ratio of p-p65/p65 protein in the SKOV3 and primary EOC cells was decreased after 30 and 50 μM ART or DHA treatment, indicating that the artemisinin derivatives decreased the p65 protein phosphorylation level in EOC cells. Thus, the artemisinin derivatives inhibited the NF-κB-signaling pathway in EOC cells.
Next, we blocked autophagy with siRNA against Atg5. The pp65/p65 and LC3-II/LC3-I ratios were measured by western blot analysis to investigate changes in the NF-κB-signaling pathway and autophagy levels, respectively. The relative LC3-II/LC3-I ratio was increased in the NC group but remained rather stable in the siAtg5 group; in contrast, the p-p65/p65 ratio was decreased in the NC group, but there was no significant difference in the siAtg5 group (Fig. 4C,D) . The results demonstrated that after knockdown of Atg5, neither ART nor DHA could activate autophagy in EOC cells, were treated with 30 μM or 50 μM ART or DHA, which caused cell cycle arrest. The x-axis represents annexin-V-FITC fluorescence, and the y-axis represents PI fluorescence. The apoptosis rates were evaluated (f, l). No significant apoptosis was observed. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant. The grayscale values of the western blots were evaluated. The amount of protein loaded was normalized to β-tubulin. The ratio of LC3-II/LC3-I and the relative intensity of Beclin-1 were standardized relative to the control group. The differences between groups were calculated, and the experiments were performed in triplicate. (C) Representative images of GFP-LC3 staining in SKOV3 (a-f) and primary EOC cells (g-l) incubated for 24 h in the absence (a, g) or presence of ART (b, c, h, i) or DHA (d, e, j, k). Rapamycin was used as a positive control for autophagy induction (f, l). Bright GFP-LC3 puncta indicated the accumulation of autophagic vacuoles. Bar, 10 μm. (D) The percentage of cells with punctuate GFP-LC3 staining was quantified. Similar to the rapamycin group, ART and DHA led to more puncta-positive cells, indicating autophagy induction. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant. and the NF-κB-signaling pathway could not be inhibited. Therefore, artemisinin derivative-induced autophagy might inhibit the NF-κB-signaling pathway in EOC cells.
Discussion
In this study, we demonstrated that the possible mechanism involved in the ovarian cancer cytotoxicity of artemisinin derivatives relies on autophagy induction. Autophagy triggers G2/M arrest in EOC cells, thus inhibiting EOC cell growth. Our findings suggest that artemisinin derivative-induced autophagy plays a role in EOC cell cycle arrest and provide new evidence that autophagy might be a candidate target in ovarian cancer therapy.
Loss of cell cycle control is one of the hallmarks of cancer cells and results in uncontrolled proliferation of tumors [23] . Therefore, the cell cycle has been a target of cancer therapy [24, 25] . Artemisinin derivatives have been reported to regulate the cancer cell cycle. DHA has been reported to cause G2/M cell cycle arrest in head and neck cancer, and this effect is mediated by Forkhead box protein M1 [26] . Artemisinin decreases Sp1 function, downregulates CDK4 expression, and triggers G1 cell cycle arrest in human prostate cancer cells [27] . Herein, we found that different concentrations of ART and DHA could inhibit EOC cell growth and induce G2/M cell cycle arrest without inducing apoptosis, suggesting that cell cycle arrest induced by ART and DHA might account for EOC cell inhibition (Fig. 1) . (C) Cell extracts were subject to western blot analysis using an antibody against Atg5. The relative Atg5 intensity was standardized to that of the NC group. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. NS, not significant. Figure 4 . The NF-κB-signaling pathway was inhibited by artemisinin derivatives in EOC cells (A) p65 phosphorylation indicates NF-κB-signaling pathway activation. SKOV3 (a) and primary EOC cells (b) were treated with 0, 30, and 50 μM ART or DHA for 24 h; then, the relative p65 and p-p65 protein expression levels were examined by western blot analysis. The amount of protein loaded was normalized to β-tubulin, and the experiments were performed in triplicate. (B) The grayscale values of the western blots were evaluated. The ratio of p-p65/p65 was reduced in a dose-dependent manner 24 h after ART or DHA treatment in SKOV3 cells (a) and primary EOC cells (b). The p-p65/p65 ratio was standardized to that of the control group, and the differences between groups were calculated. The experiments were performed in triplicate. (C) SKOV3 cells (a, b) and primary EOC cells (c, d) were transiently transfected with siRNA against Atg5 and then treated with the artemisinin derivatives at different concentrations for 24 h. Western blot anaysis was performed to determine the protein levels of p-p65, p65, and LC3. The amount of protein loaded was normalized to β-tubulin, and the experiments were performed in triplicate. (D) The grayscale values of the western blots were evaluated. The ratios of p-p65/p65 and LC3-II/LC3-I were standardized to those of the control group. The relative LC3-II/LC3-I ratio was increased in the NC group but remained stable in the siAtg5 group. In contrast, the p-p65/p65 ratio was decreased in the NC group, but there was no significant difference between the control group and the siAtg5 group. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
According to the current studies, autophagy can be induced by artemisinin and its derivatives in cancer cells; however, whether there is a target in this antitumor effect is unclear. Ganguli et al. [28] reported that pretreatment with CQ had synergistic effects on ART treatment in non-small lung carcinoma cells. In a study of the HeLa human cervical cell line, autophagy inhibition with CQ enhanced the anticancer effects of DHA [29] . Feng et al. [30] reported that DHA induced autophagy in ovarian cancer cells; however, the suppression of autophagic flux did not reduce cancer cell death. Herein, we observed that the artemisinin derivatives ART and DHA can induce autophagy in EOC cells at different concentrations (Fig. 2) , and the antitumor effects of these artemisinin derivatives can be reversed by autophagy inhibitors (Fig. 3) . These results suggest that autophagy induction may be the mechanism underlying the antitumor effects of artemisinin derivatives, thus revealing a potential new mechanism of action of antimalarial drugs in ovarian cancer.
NF-κB can suppress cell death pathways, decrease apoptosis, and promote cell growth; thus, it is widely accepted as a tumor promoter [31] . In the present study, we confirmed that the NF-κB-signaling pathway could be suppressed by ART and DHA in EOC cells, and blocking autophagy eliminated this modulation (Fig. 4) , suggesting that autophagy induced by artemisinin derivatives may lead to NF-κB inhibition. Additionally, the NF-κB-signaling pathway is reportedly related to cell cycle regulation. Cude et al. [32] demonstrated that NF-κB-mediated transcription regulates G2/M progression. Inhibition of NF-κB delays mitotic entry and inhibits the transcription of certain crucial genes involved in the G2/M phase. In cells undergoing hepatocarcinogenesis, butaselen-mediated NF-κB pathway inhibition could lead to G2/M arrest [33] . Thus, autophagy-induced NF-κB inhibition might be related to G2/M arrest in artemisinin derivative-treated EOC cells.
Whether autophagy is a friend or foe in cancer remains controversial. Autophagy may act as a protective mechanism in cancer in response to stress, for example, by maintaining cancer stem cells and inducing chemoresistance [34] . Additionally, it has been reported that blocking autophagy enhances the effect of cisplatin in BRCA2-silenced ovarian cancer cells [35] . However, there is evidence that autophagy plays a role in ovarian cancer suppression. Resveratrol can epigenetically upregulate autophagy in ovarian cancer to produce migration-inhibiting effects [36] . Lu et al. [37] found that autophagic cell death occurs when autophagy is induced to a certain level in SKOV3 cells. A 15-kDa phosphoprotein, phosphor-enriched protein in astrocytes (PEA-15), induces autophagy in ovarian cancer, and high levels of PEA-15 expression are positively correlated with longer survival in patients [38] . Alisertib, a selective Aurora kinase A inhibitor, was reported to arrest SKOV3 and OVCAR4 cells in the G2/M phase and promote autophagy [39] . The combination of decitabine and suberoylanilide hydroxamic acid was found to induce autophagy and inhibit cancer cell growth in ovarian cancer cell lines (HEY and SKOV3) [40] . In addition, knockdown of the RAB25 gene with siRNA could induce autophagy in HEY and ES-2 ovarian cancer cells and increase the proportion of cells in the G0/ G1 phase [41] . Consistent with these results, our findings also suggest that it is feasible to suppress ovarian cancer cells by inducing autophagy.
Increasing evidence shows that artemisinin derivatives have great potential as anticancer therapies. Because there are many targets of the anticancer effects of artemisinin derivatives, it is worth seeking combinations of cancer therapies. For example, ART enhances the responsiveness of glioblastoma cells to the cytotoxicity of temozolomide [42] . The interactions between halofuginone and artemisinin have a synergistic anticancer effect in various cancer cells by regulating the cell cycle [43] . Herein, we demonstrate that the autophagy inhibitor CQ counteracts the EOC cell inhibition induced by ART and DHA. However, whether artemisinin derivatives combined with other anticancer agents could improve the efficiency of anticancer therapies should be further investigated. Furthermore, it is worth exploring whether artemisinin derivatives suppress EOC cells through other pathways when autophagy is blocked [44] .
In conclusion, artemisinin derivatives induce autophagy in EOC cells, thereby blocking the cell cycle and ultimately inhibiting cancer cell growth. Our research reveals a new target for artemisinin in EOC treatment.
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